Deadline on June 18, 2021 coming up in Lawsuit for Investors in Emergent BioSolutions Inc (NYSE: EBS)

A deadline is coming up on June 18, 2021in the lawsuit filed for certain investors of Emergent BioSolutions Inc (NYSE: EBS) over alleged securities laws violations by Emergent BioSolutions Inc.

Investors who purchased shares of Emergent BioSolutions Inc (NYSE: EBS) have certain options and there are strict and short deadlines running. Deadline: June 18, 2021. NYSE: EBS stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

According to the complaint filed in the U.S. District Court for the District of Maryland the plaintiff alleges on behalf of purchasers of Emergent BioSolutions Inc (NYSE: EBS) common shares between July 6, 2020 and March 31, 2021, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between July 6, 2020 and March 31, 2021, the ompany failed to disclose to investors myriad issues at Bayview that would detrimentally affect its ability to manufacture the vaccine. Investors began to learn the truth on March 31, 2021, after the close of markets, when media reports revealed that employees at Emergent’s Bayview facility “mixed up” ingredients for the J&J and AstraZeneca vaccines, contaminating up to 15 million doses of the J&J vaccine. It was further revealed that this was not an isolated incident and part of a history of manufacturing issues at the Company’s plant. Media outlets called the massive contamination a “significant setback and public relations debacle” and highlighted longstanding contamination risks and quality control issues at the Company’s facilities, leading to a string of FDA citations, including a persistent problem with mold, poor disinfection of some plant equipment leading to growth of bacteria, the repeated approval of raw materials that had not been fully tested, and poor employee training.

Shares of Emergent BioSolutions Inc (NYSE: EBS) declined on April 22, 2021, to as low as $61.00 per share.

Those who purchased shares of Emergent BioSolutions Inc (NYSE: EBS) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.